Recent Updates
Recently added Catalysts

IPH4502

Phase 1

Advanced or Metastatic Solid Tumors | Small molecule | Oncology |Innate Pharma S.A.|Last Updated: Jan 7, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment145
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06781983Safety and Tolerability of IPH4502 in Patients With Advanced Solid TumorsPHASE1 RECRUITING 145 — — Jan 24, 2025Apr 1, 2029Jan 7, 20267 United States, France
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety and Tolerability
From time of first dose through treatment period, including the follow-up: up to 24 months

To evaluate the incidence of AEs, SAEs, TEAEs, and DLTs.

Secondary Endpoints
Maximum Observed Plasma Concentration (Cmax)
From time of informed consent through treatment period, including the follow-up: up to 24 months
Area Under the Plasma Concentration (AUC)
From time of informed consent through treatment period, including the follow-up: up to 24 months
Incidence of antidrug antibodies (ADA) against IPH4502
From time of informed consent through treatment period, including the follow-up: up to 24 months
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
IPH4502 MonotherapyEXPERIMENTAL -
Interventions
NameTypeDescription
IPH4502DRUGPart 1 (dose escalation) and Part 2 (dose optimization)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites7

Main Inclusion Criteria: * Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4 * Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available....

Countries:United StatesFrance
Unlock Eligibility Criteria
Competitive Landscape -Other Solid Tumors 9 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab, V503, GARDASIL
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
AstraZeneca PLCAZN1 — Trastuzumab deruxtecan
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06781983primaryCompletionDate: changed
LOWMay 24, 2026NCT06781983studyFirstPostDate: changed